Product Data Sheet

Product Name: Naxitamab
Cat. No.: GC68338

Chemical Properties

Cas. No.	1879925-92-4		
Formula		M.Wt	
Solubility		Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	Naxitamab		

Background

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the **disialoganglioside GD2**. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1].

Naxitamab (Hu3F8; 72 h) has cytotoxicity against neuroblastoma cell line LAN-1 with an EC_{50} value of 5.1 μg/mL[1].
Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) has antibody-dependent cell-mediated cytotoxic effects (ADCC)[1].

Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts[1].

Animal Model:	Female athymic nude mice with LAN-1 xenografts[1]
Dosage:	100 mg/kg
Administration:	Intravenous injection; twice a week, for 4 weeks

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Result:	Inhibited tumor growth and prolonged the survival time.

[1]. Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1;1(4):477-486.
[2]. Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81(2):291-296.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA